In this CME/CE-accredited Interactive Case Challenge, explore a patient-centered approach to diagnosing and managing MASH using guideline-recommended noninvasive testing.
Learning objectives:
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Metabolic dysfunction associated steatohepatitis. Upon completion of this activity, participants should be able to:
- Employ guideline-recommended noninvasive testing to risk stratify, diagnose, and monitor patients with MASH
- Apply strategies to achieve recommended weight loss to target the underlying pathophysiology of MASH
Faculty:
Scott L. Friedman, MD
Dean for Collaborative Research and Partnerships
Fishberg Professor of Medicine
Professor of Pharmacologic Sciences
Director, Institute for Liver Research
Co-Director, Cancer Mechanisms Program, Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York
Supporters:
Supported by an educational grant from Novo Nordisk.
Sponsor:
Provided by Clinical Care Options, LLC in partnership with AGA
Released: July 14, 2025
Expiration: July 13, 2026
Primary Author
Scott L. Friedman, MD: consultant/advisor/speaker: 89 Bio, AbbVie, AGED Diagnostics, Boehringer Ingelheim, Boston Pharmaceuticals, Curie Bio, Engine Biosciences, Gordian Biotechnology, Hepta, Insitro, Junevity, Korro, Kriya, Macomics, Merck, Metrea, Moderna, Morphic Therapeutics, North Sea Therapeutics, Ochre, Overtone Therapeutics, Pfizer, Prosciento Research, Resolution Therapeutics, Satellite Bio, Sunbird, Surrozen, Takeda, Therasid, Variant; individually traded stock/stock options: Blade Therapeutics, Escient, Galectin, Galmed, Genfit, Glympse, HepGene, Laekna, LifeMax, Metacrine, Morphic Therapeutics, Nimbus, North Sea Therapeutics, Satellite Bio, Scholar Rock, Surrozen; researcher: Abalone, Novo Nordisk.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES, as noted below:
Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES: consultant/advisor/speaker: Abbott, Novo Nordisk, Xeris.
